Mission/Vision position: Support development of an antibody platform to enable researchers to develop antibodies for therapeutic and diagnostic applications and validation tools and bridge the gap between academic research and pharma applications.
Interest: Antibodies in Immuno-oncology & Autoimmunity. Bridge the gap between Academic Research and Biotech/Pharma applications
Background: Antibodies represent a revolutionary and effective therapeutic and diagnostic approach. With currently more than 100 therapeutic antibodies approved it is the fastest growing class of new therapeutics. Antibodies can be applied as validation tools of new concepts but also can be the starting point for development of diagnostic and therapeutic agents. Antibody Phage display technology is a very powerful technology to select target specific human antibodies for therapeutic as well as diagnostic applications and from a previous human antibody library made at Dyax (Now Shire) (see Hoet et al. Nat. Biotech 2005, 23, 344–348 (2005) 4 antibodies have been FDA approved and more than 10 antibodies are still in various stages of clinical trial.
Aim is to expand antibody technologies to use for new applications in order to complement current lead discovery activities in the Pathology Department. But obviously, this technology development will benefit many other areas of research at the UM/AZM.
René Hoet is extraordinary Professor Biopharmaceutics at the University of Maastricht, Netherlands, guiding researchers to use antibodies to bridge the gap between academic research and pharmaceutical applications.
Since April 1 2021 Rene works as Chief Scientific Officer at Montis Biosciences, Leuven, Belgium to develop the next generation Immuno-Oncology drugs using a novel approach interfering in the Tumor Endothelial Cell and Perivascular Macrophage Interactions to restore a immunocompetent tumor microenvironment.
Prior to this he worked as Chief Scientific Officer for Imcheck Therapeutics (Oct 2018- April 2021) developing the first gamma delta T cell activating antibody from preclinical stage into the clinic. Before joining ImCheck, René spent 8 years at Bayer AG as Vice President Biologics Research, where his team was responsible for antibody lead discovery and optimization developing multiple antibodies from discovery into the clinic in Hematology, Cardiology, Gynecology, Immuno-Oncology and Autoimmunity. Between 2008-2010, he was a member of the management team at Genmab and as Senior Director Research led the team Product Related Research, Scientific Communication & Translational Research. Together with his team, he ran the antibody discovery programs and actively supported Genmab’s clinical antibody programs. René started his industrial career at Target Quest (acquired by Dyax in 1999) where his last position was Vice President Research and Operational Manager of Dyax SA. He was the driving force for internal antibody lead discovery as well as external collaborations and supported the out-licensing of Dyax’ antibody phage libraries. From these libraries, 4 antibodies have been approved by the FDA & EMA and over 10 antibodies from varies companies are currently in clinical trials.
Deelnames, projecten en nevenfuncties
Teaching Activities Prof. Rene Hoet
- Teaching courses University Maastricht Immune System BGK Bachelor students. Biologics (2013, 2014-2018)
- Teaching course BMS Master Inflammation and Pathophysiology; Therapeutic Antibodies, 2019, 2020, 2021)
- Teaching Course Medical Students (Bachelor) Drugs in the clinics Maastricht University; -Therapeutic Development of Antibodies, From Target to Drug Approval (2014-2015-2016, 2018)
- Teaching Biomedical students (Bachelor): Research methods in molecular neuroscience and toxicology. Maastricht University. 2015, 2018
- Teaching PhD day June, 2015 Maastricht University: Opportunities in Bayer. Internships and research within or funded by a company.
- Career in Pharma Industry: Rene Hoet, University Nijmegen, 2014 & 2016
- Teaching Course Medical Biotechnology: Therapeutic Antibody Development, Bachelor Course, University Nijmegen (2014-2021)
Collaboration with Biotech Companies
Lead collaborations Immuno-oncology Butyrophilins between Imcheck Therapeutics and Prof. Erik Biessen & Pieter Goossens, Pathology
Lead Collaboration Autoimmunity Butyrophilins between Imcheck Therapeutics & Prof. P. Martinez, Dr. M. Lozen